Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
71.05
+0.49 (0.69%)
Nov 20, 2024, 4:00 PM EST - Market open
Incyte Employees
Incyte had 2,524 employees as of December 31, 2023. The number of employees increased by 200 or 8.61% compared to the previous year.
Employees
2,524
Change (1Y)
200
Growth (1Y)
8.61%
Revenue / Employee
$1,614,842
Profits / Employee
$12,869
Market Cap
13.69B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Tenet Healthcare | 106,500 |
Universal Health Services | 96,700 |
Viatris | 38,000 |
Revvity | 11,500 |
Avantor | 7,570 |
Moderna | 5,600 |
Genmab | 2,204 |
Insmed | 912 |
INCY News
- 1 day ago - Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study - Investopedia
- 1 day ago - Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock. - Barrons
- 1 day ago - Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges - Benzinga
- 2 days ago - Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs - Business Wire
- 7 days ago - Incyte to Present at Upcoming Investor Conference - Business Wire
- 13 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff - Seeking Alpha
- 21 days ago - Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock - Benzinga